Edition:
United States

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.10USD
23 Feb 2018
Change (% chg)

$0.05 (+2.44%)
Prev Close
$2.05
Open
$2.05
Day's High
$2.10
Day's Low
$2.00
Volume
27,172
Avg. Vol
78,395
52-wk High
$3.60
52-wk Low
$1.58

Chart for

About

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products... (more)

Overall

Beta: 0.58
Market Cap(Mil.): $117.36
Shares Outstanding(Mil.): 55.88
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.96 16.59
EPS (TTM): -- -- --
ROI: -- 14.08 35.07
ROE: -- 15.71 17.79

BRIEF-Biodelivery Sciences Announces Belbuca Patent Litigation Settlement Agreement With Teva

* BIODELIVERY SCIENCES ANNOUNCES BELBUCA PATENT LITIGATION SETTLEMENT AGREEMENT WITH TEVA

Feb 06 2018

BRIEF-BioDelivery Sciences Announces Launch And Availability Of Belbuca In Canada

* BIODELIVERY SCIENCES ANNOUNCES LAUNCH AND AVAILABILITY OF BELBUCA® IN CANADA Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical

* BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL

Dec 14 2017

BRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary

* BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL

Nov 27 2017

BRIEF-BioDelivery Sciences reports Q3 loss per share $0.21

* BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update

Nov 09 2017

BRIEF-BioDelivery sciences announces patent litigation settlement agreement with Teva

* BioDelivery Sciences announces patent litigation settlement agreement with Teva

Oct 12 2017

Earnings vs. Estimates